The lack of a control group without ACE inhibitor and ARB was justified by results of previous randomized controlled trials demonstrating a protective effect of either ACE inhibitor or ARB treatment over placebo against microalbuminuria development in patients with type 2 diabetes [27]. This evidence concerns the gene ACE and type 2 diabetes mellitus.